Edition:
United States

Julie Steenhuysen

Lynparza stalls pancreatic cancer in patients with BRCA mutations: study

Jun 02 2019

CHICAGO AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go nearly twice as long without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

CORRECTED-Lynparza stalls pancreatic cancer in patients with BRCA mutations -study

Jun 02 2019

CHICAGO, June 2 AstraZeneca and Merck & Co's Lynparza helped patients with advanced pancreatic cancer who carry BRCA gene mutations go longer without their disease worsening than those who received a placebo, according to data from a late-stage clinical trial presented on Sunday.

Merck's Keytruda sets new five-year survival standard for advanced lung cancer

Jun 01 2019

CHICAGO Nearly a quarter of patients who received Merck & Co's immunotherapy Keytruda as an initial treatment for advanced lung cancer were still alive after five years, according to data presented at a major medical meeting on Saturday.

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

May 10 2019

INDIANAPOLIS Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients.

Lilly's new migraine drug pulls ahead of Amgen in fierce battle for new prescriptions

May 10 2019

INDIANAPOLIS, May 10 Eli Lilly and Co has pulled ahead in a three-way race with Amgen Inc and Teva Pharmaceutical Industries Ltd in attracting new patients to a new class of migraine drugs, and seeks to build on that advantage by stressing that its therapy can completely prevent headaches in a small percentage of patients. Weekly U.S. prescription data from IQVIA, an analytics provider to the life sciences industry, showed that Lilly’s therapy Emgality claimed the largest share of first-time patients at 37.7 percent, for the first time outstripping Amgen’s Aimovig, whose share dropped to 37.2 percent as of April 26. Teva came in at a 25.1 percent share, according to an analyst who reviewed the data.

U.S. doctors use medical records to fight measles outbreak

May 06 2019

CHICAGO U.S. doctors are tapping into their electronic medical records to identify unvaccinated patients and potentially infected individuals to help contain the worst U.S. measles outbreak in 25 years.

Sanofi wins U.S. approval to sell dengue vaccine but with major restrictions

May 01 2019

CHICAGO The U.S. Food and Drug Administration on Wednesday gave Sanofi SA's dengue vaccine Dengvaxia a very narrow approval as the company continues to suffer from evidence that its vaccine, which took 20 years to develop, can cause severe infections in some people.

Eli Lilly misses estimates for top-selling diabetes drug Trulicity, shares slip

Apr 30 2019

Eli Lilly and Co on Tuesday reported lower-than-expected first-quarter sales for its top-selling diabetes drug Trulicity, and the U.S. drugmaker said the need to offer rebates and discounts were taking a toll and likely to weigh on revenue growth for the year.

World News